Acitretin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Acitretin: From Psoriasis to Acne
One-Sentence Summary
Acitretin is a second-generation oral retinoid (synthetic vitamin A derivative), established internationally for severe psoriasis and disorders of keratinisation, though it is not currently registered in Singapore. The TxGNN model predicts it may be effective for acne (disease), with 1 clinical trial and 18 publications identified in support; however, the sole clinical trial concerns isotretinoin rather than acitretin, and the majority of literature addresses acne inversa (hidradenitis suppurativa) rather than typical acne vulgaris — a clinically important distinction. Overall evidence is rated L4 (mechanistic and preclinical), and the current recommendation is to treat this as a Research Question requiring further differentiation before clinical development.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in Singapore; internationally established for psoriasis and disorders of keratinisation |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L4 |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold (Research Question) |
Why is This Prediction Reasonable?
Currently, formal mechanism of action data from DrugBank is not available for this analysis. Based on known pharmacological information, Acitretin is a second-generation aromatic retinoid that activates nuclear retinoic acid receptors (RARα, RARβ, RARγ). Through RAR signalling, it modulates sebaceous gland activity, normalises follicular keratinisation, and suppresses inflammatory mediator release (including leukotriene LTC4 from eosinophils) — all of which are pathways directly relevant to the pathogenesis of acne.
The TxGNN model's high prediction score of 99.94% reflects the strong mechanistic overlap between retinoid pharmacology and acne-related nodes in the knowledge graph. Acitretin and the well-known acne drug isotretinoin belong to the same retinoid class; both suppress sebaceous gland activity via RAR, and both exert anti-inflammatory effects. The mechanistic bridge is therefore biologically plausible. Several reviews confirm that oral retinoids — including acitretin — have been used in acne-related dermatoses.
However, a critical clinical nuance must be acknowledged: existing evidence predominantly supports Acitretin for acne inversa (hidradenitis suppurativa, HS), not typical acne vulgaris. For acne vulgaris, isotretinoin retains a markedly stronger and more selective effect on sebaceous glands and is the approved standard of care. Acitretin's primary niche within the acne spectrum appears to be the follicular inflammation of HS, where at least one 25-year case series and multiple clinical guidelines cite it as a treatment option. Any repurposing development pathway must first resolve this distinction.
Clinical Trial Evidence
⚠️ Important caveat: The single retrieved trial concerns isotretinoin, not acitretin. No registered clinical trials directly evaluating Acitretin for acne (vulgaris or inversa) were identified.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04663906 | N/A | Unknown | 300 | Investigates whether oral isotretinoin (not acitretin) increases COVID-19 infection risk via retinoid-induced mucosal dryness in acne patients; no direct relevance to acitretin efficacy in acne |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20874789 | 2011 | Clinical Study | Br J Dermatology | 25-year case experience of acitretin therapy for hidradenitis suppurativa (acne inversa); suggests limited but clinically meaningful benefit; questions whether HS is truly "acne inversa" |
| 12080949 | 2002 | Case Report | Cutis | Nodulocystic acne and HS treated with acitretin after failure of two isotretinoin courses; partial response observed, supporting use in refractory cases |
| 25640693 | 2015 | Clinical Guideline | JEADV | European S1 guideline for HS/acne inversa; acitretin included as a systemic treatment option within the management algorithm |
| 29234829 | 2018 | Narrative Review | Hautarzt | Drug therapy of acne inversa; acitretin discussed alongside antibiotics and TNF-α inhibitors as a systemic option |
| 26617362 | 2016 | Review | Dermatologic Clinics | Medical treatments of HS; emphasises low evidence levels across all therapies including acitretin; calls for validation in RCTs |
| 8573927 | 1995 | Mechanistic Review | Dermatology | Retinoids and sebaceous gland activity; isotretinoin has greater sebaceous suppression potency than acitretin — key mechanistic distinction |
| 2112772 | 1990 | Mechanistic Study | Prostaglandins | Acitretin shown to inhibit eosinophil LTC4 release; supports anti-inflammatory rationale relevant to acne pathogenesis |
| 9074840 | 1997 | Review | Drugs | Comprehensive retinoid review; acitretin's role in hyperkeratotic and acne-related dermatoses summarised; second-generation retinoid status confirmed |
| 1617858 | 1992 | Review | Clin Pharmacokinet | Pharmacokinetics and efficacy of retinoids in skin diseases; acitretin versus etretinate for psoriasis, isotretinoin for acne — highlights different primary indications within the class |
| 41692081 | 2026 | Review | Clinics in Dermatology | Vitamin A and retinoids in dermatology; acitretin listed as oral retinoid therapeutic agent alongside isotretinoin; acne management context discussed |
Singapore Market Information
Acitretin is currently not registered in Singapore. No product authorisations were found in the Singapore Health Sciences Authority (HSA) database.
Any clinical use or research use of Acitretin in Singapore would require a Special Access Route (SAR) application or a clinical trial import licence. Procurement and regulatory pathway development would be required before any clinical programme can commence.
Safety Considerations
Please refer to the package insert for safety information.
Critical safety flag (publicly known): Acitretin is classified as a Pregnancy Category X drug — it is a potent teratogen causing axial skeletal, craniofacial, and cardiac malformations. It is absolutely contraindicated in pregnancy and in women of childbearing potential who cannot comply with rigorous contraception protocols. A minimum washout period of 2–3 years after discontinuation is required before conception is considered safe (due to esterification back to the long-acting teratogen etretinate in the presence of alcohol). This safety profile has major implications for any repurposing programme in acne, where the patient population frequently includes women of reproductive age.
Conclusion and Next Steps
Decision: Hold (Research Question)
Rationale: Evidence for Acitretin in acne remains at L4 (mechanistic reviews and isolated case reports), with no registered clinical trials directly evaluating the drug for any acne subtype. Critically, the mechanistic and clinical evidence base overwhelmingly concerns acne inversa (hidradenitis suppurativa) rather than acne vulgaris — these are distinct diseases with different pathophysiology and treatment standards. Furthermore, Acitretin's severe teratogenicity poses a substantial population-level safety constraint in any acne indication, where female patients of childbearing age represent a core demographic.
To proceed, the following is needed:
- Clarify the target indication: acne vulgaris vs. acne inversa/hidradenitis suppurativa must be formally separated — these require entirely different evidence development pathways and patient selection criteria
- Resolve Data Gap DG002: Obtain formal MOA data from DrugBank API to confirm the RAR-sebaceous-follicular mechanism and distinguish it from isotretinoin's profile
- Resolve Data Gap DG001: Obtain full prescribing information (package insert) including warnings, contraindications, and monitoring requirements before any safety assessment (currently Blocking severity)
- Conduct a focused systematic review of acitretin in HS specifically — sufficient case series exist to potentially support an L3 evidence upgrade if rigorously synthesised
- Comparative analysis against isotretinoin: define any clinical scenario where acitretin offers a meaningful advantage over the approved standard of care for acne
- Risk–benefit assessment for reproductive-age women: given Category X status, any development programme must include a robust Pregnancy Prevention Programme (PPP) modelled on established frameworks (e.g., EU DHPC protocols for retinoids)
- Register with HSA Special Access Route if any pilot clinical evaluation in Singapore is planned
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.